Our portfolio companies are currently developing diagnostics for early detection of cancer via blood sample, saving lives in emergency care and surgery through software innovations, developing personalised treatments of severe diseases, and much more.
Capitainer develops and sells intelligent solutions for self-sampling blood, plasma, and urine. The products enable easy home sampling with market-leading precision, delivering value across the entire care chain.
PharmNovo is a pharmaceutical company at the clinical stage of developing a unique type of treatment for nerve pain (neuropathic pain), a condition currently lacking effective and safe treatment. The company is currently finalising its clinical phase I study and is advancing its preparations for a phase II study.
NEOGAP Therapeutics develops a new type of personalised therapy for the treatment of cancer. The company uses proprietary machine learning algorithms and patented technology to tailor the treatment for each patient and its specific tumour cells.
Encare not only contributes to more cost-effective surgery but also reduces complications and saves lives through their proprietary software solution that helps hospitals implement best practice throughout the entire care chain – from diagnosis and preparation to surgery and rehabilitation.
Former portfolio companies that have reached new heights through acquisition or listing, and continue to thrive under new ownership. These companies continue to make a lasting impact in their respective industries.
Inhalation Science’s technology is used by leading players in the chemical and pharmaceutical sectors to study how airborne particles affect the human body.
